Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Italian Journal of Pediatrics

Volumn 39, Issue 1, 2013, Pages

  Moavero, Romina ^a   Coniglio, Antonella ^a   Garaci, Francesco ^a   Curatolo, Paolo ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Epilepsy; Everolimus; mTOR inhibitors; Renal angiomyolipomas; SEGA; Treatment; Tuberous sclerosis

Indexed keywords

EVEROLIMUS; PLACEBO; RAPAMYCIN;

ANGIOMYOLIPOMA; AUTISM; CLINICAL PRACTICE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FOCAL EPILEPSY; HEART TUMOR; HEMANGIOFIBROMA; HUMAN; HYDROCEPHALUS; INFANTILE SPASM; KIDNEY DISEASE; KIDNEY TUMOR; LYMPHANGIOMYOMA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RHABDOMYOMA; SEIZURE; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 84883893194     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-39-57     Document Type: Review

References (39)

1. Tuberous sclerosis. Curatolo P, Bombardieri R, Jozwiak S, Lancet 2008 372 657 668 10.1016/S0140-6736(08)61279-9 18722871
2. Epidemiology of tuberous sclerosis. Osborne JP, Fryer A, Webb D, Ann N Y Acad Sci 1991 615 125 127 10.1111/j.1749-6632.1991.tb37754.x 2039137
3. Increased brain apparent diffusion coefficient in tuberous sclerosis. Garaci FG, Floris R, Bozzao A, Manenti G, Simonetti A, Lupattelli T, Curatolo P, Simonetti G, Radiology 2004 232 461 465 10.1148/radiol.2322030198 15215545 (Pubitemid 38971287)
4. The tuberous sclerosis complex. Crino PB, Nathanson KL, Henske EP, N Engl J Med 2006 355 1345 1356 10.1056/NEJMra055323 17005952 (Pubitemid 44465463)
5. Recent advances in neurobiology of tuberous sclerosis complex. Napolioni V, Moavero R, Curatolo P, Brain Dev 2009 31 104 113 10.1016/j.braindev.2008.09. 013 19028034
6. Causes of death in patients with tuberous sclerosis. Shepherd CW, Gomez MR, Lie JT, Crowson CS, Mayo Clin Proc 1991 66 792 796 10.1016/S0025-6196(12) 61196-3 1861550
7. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Moavero R, Pinci M, Bombardieri R, Curatolo P, Childs Nerv Syst 2011 27 1203 1210 10.1007/s00381-011-1406-0 21305305
8. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Lancet 2013 381 116 23312754
9. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN, N Engl J Med 2010 363 1801 1811 10.1056/NEJMoa1001671 21047224
10. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Zeng LH, Xu L, Gutmann DH, Wong M, Ann Neurol 2008 63 444 453 10.1002/ana.21331 18389497 (Pubitemid 351614710)
11. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS, Neurobiol Dis 2011 43 322 329 10.1016/j.nbd.2011.03.021 21504792
12. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Ryther RC, Wong M, Curr Neurol Neurosci Rep 2012 12 410 418 22544534
13. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Perek-Polnik M, Jozwiak S, Jurkiewicz E, Perek D, Kotulska K, Eur J Paediatr Neurol 2012 16 83 85 10.1016/j.ejpn.2011.09.006 22000822
14. Rapamycin reduces seizure frequency in tuberous sclerosis complex. Muncy J, Butler IJ, Koenig MK, J Child Neurol 2009 24 477 10.1177/0883073808324535 19151365
15. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. Curatolo P, Napolioni V, Moavero R, J Child Neurol 2010 25 873 880 10.1177/0883073810361789 20207609
16. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Jansen FE, Vincken KL, Algra A, Anbeek P, Braams O, Nellist M, Zonnenberg BA, Jennekens-Schinkel A, van den Ouweland A, Halley D, et al. Neurology 2008 70 916 923 10.1212/01.wnl.0000280579.04974.c0 18032744 (Pubitemid 351430755)
17. The natural history of epilepsy in tuberous sclerosis complex. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA, Epilepsia 2010 51 1236 1241 20041940
18. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Cusmai R, Moavero R, Bombardieri R, Vigevano F, Curatolo P, Epilepsy Behav 2011 22 735 739 10.1016/j.yebeh.2011.08.037 22142783
19. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P, Eur J Paediatr Neurol 2010 14 146 149 10.1016/j.ejpn.2009.03.003 19369101
20. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Sato A, Kasai S, Kobayashi T, Takamatsu Y, Hino O, Ikeda K, Mizuguchi M, Nat Commun 2012 3 1292 23250422
21. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ, Nat Med 2008 14 843 848 10.1038/nm1788 18568033
22. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, Klein PM, Lan VJ, Joseph A, Jensen FE, PLoS One 2012 7 35885 10.1371/journal.pone.0035885 22567115
23. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J, J Child Neurol 2000 15 652 659 10.1177/088307380001501003 11063078
24. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. N Engl J Med 2008 358 140 151 10.1056/NEJMoa063564 18184959
25. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Clin Cancer Res 2011 17 4071 4081 10.1158/1078-0432.CCR-11-0445 21525172
26. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Lancet 2013 381 817 824 10.1016/S0140-6736(12)61767-X 23312829
27. The cutaneous features of tuberous sclerosis: a population study. Webb DW, Clarke A, Fryer A, Osborne JP, Br J Dermatol 1996 135 1 5 9035700 (Pubitemid 26225105)
28. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. Kaufman McNamara E, Curtis AR, Fleischer AB Jr, J Dermatolog Treat 2012 23 46 48 10.3109/09546634.2010.489598 20673154
29. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wuthrich RP, Serra AL, Br J Dermatol 2008 159 473 475 10.1111/j.1365-2133.2008.08677.x 18547304 (Pubitemid 352009863)
30. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Haemel AK, O'Brian AL, Teng JM, Arch Dermatol 2010 146 715 718 10.1001/archdermatol.2010.125 20644030
31. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. DeKlotz CM, Ogram AE, Singh S, Dronavalli S, MacGregor JL, Arch Dermatol 2011 147 1116 1117 21931059
32. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I, Arch Dermatol 2012 148 138 139 10.1001/archderm.148.1.138 22250258
33. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Jozwiak S, Kotulska K, Kasprzyk-Obara J, Domanska-Pakiela D, Tomyn-Drabik M, Roberts P, Kwiatkowski D, Pediatrics 2006 118 1146 e1151 10.1542/peds.2006-0504 16940165 (Pubitemid 46393764)
34. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Tiberio D, Franz DN, Phillips JR, Pediatrics 2011 127 1335 e1337 10.1542/peds.2010-2910 21464184
35. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. N Engl J Med 2011 364 1595 1606 10.1056/NEJMoa1100391 21410393
36. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Neurohr C, Hoffmann AL, Huppmann P, Herrera VA, Ihle F, Leuschner S, von Wulffen W, Meis T, Baezner C, Leuchte H, et al. Respir Res 2011 12 66 10.1186/1465-9921-12-66 21600034
37. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J, Ann Intern Med 2011 154 797 805 W-292-793 10.7326/0003-4819-154-12-201106210-00007 21690594
38. mTOR inhibitors in tuberous sclerosis complex. Curatolo P, Moavero R, Curr Neuropharmacol 2012 10 404 415 23730262
39. Rapamycin: something old, something new, sometimes borrowed and now renewed. Hartford CM, Ratain MJ, Clin Pharmacol Ther 2007 82 381 388 10.1038/sj.clpt.6100317 17728765 (Pubitemid 47414349)